Conference Coverage

Conference Coverage

TECOS finds no CV risks for sitagliptin

Key clinical point: Sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor used to lower blood glucose in patients with type 2 diabetes, was not...

Pages